Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Yu, Shaorong ^a,b   Xiao, Xia ^a   Lu, Jianwei ^a   Qian, Xiaoping ^b   Liu, Baorui ^b   Feng, Jifeng ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CLINICAL ARTICLE; CODON; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA EXTRACTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; METASTASIS POTENTIAL; METASTATIC COLORECTAL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PYROSEQUENCING; RETROSPECTIVE STUDY; TUMOR CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84879903169     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068022     Document Type: Article

References (22)

1. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, et al. (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474.
2. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A, (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-862.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
4. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
5. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
6. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.
7. Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, et al. (2012) KRAS p. G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer. Cancer epub ahead of print.
8. Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, et al. (2012) Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation. Oncol Lett 3: 269-272.
9. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, et al. (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30: 3570-3577.
10. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, et al. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820.
11. Chen J, Ye Y, Sun H, Shi G, (2013) Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 71: 265-272.
12. Modest DP, Brodowicz T, Stintzing S, Jung A, Neumann J, et al. (2012) Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. Oncology 83: 241-247.
13. Nordgard O, Oltedal S, Janssen EA, Gilje B, Korner H, et al. (2012) Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations. Diagn Mol Pathol 21: 9-13.
14. Kobunai T, Watanabe T, Yamamoto Y, Eshima K, (2010) The frequency of KRAS mutation detetion in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun 395: 158-162.
15. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, et al. (2011) Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 29: 3316-3321.
16. Yu S, Wu J, Xu S, Tan G, Liu B, et al. (2012) Modified PNA-PCR method: a convenient and accurate method to screen plasma KRAS mutations of cancer patients. Cancer Biol Ther 13: 314-320.
17. Yu S, Xie L, Hou Z, Qian X, Yu L, et al. (2011) Coamplification at lower denaturation temperature polymerase chain reaction enables selective identification of K-Ras mutations in formalin-fixed, paraffin-embedded tumor tissues without tumor-cell enrichment. Hum Pathol 42: 1312-1318.
18. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, et al. (2011) Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 17: 4901-4914.
19. Kristensen LS, Kjeldsen TE, Hager H, Hansen LL, (2012) Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer. BMC Cancer 12: 548.
20. Nordgard O, Oltedal S, Janssen EA, Gilje B, Korner H, et al. (2012) Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations. Diagn Mol Pathol 21: 9-13.
21. Pritchard CC, Akagi L, Reddy PL, Joseph L, Tait JF, (2010) COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma. BMC Clin Pathol 10: 6.
22. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536.